Let's improve life for all
Hands-on investing in and mentoring of the world’s next great biotech innovators to achieve the betterment of all involved.All Projects
Duggan Investments is a hands-on, active investment company, headed by Robert Duggan, who has many decades of success and experience.
An example: Under Bob’s guidance, Pharmacyclics' stock price increased from $0.57 a share in Feb 2009, to $261.25 a share in May 2015. Pharmacyclics and its "miracle drug" IMBRUVICA® were acquired by AbbVie for $21 billion in May 2015. As of today, IMBRUVICA® continues its dramatic growth and success, with use in widening indications.
Duggan Investments’ current projects are focused on cutting-edge biosciences. These include groundbreaking developments in cancer treatment, anti-microbial advancements, anti-aging technologies, and stem cell research.
Selective. Results-driven. Successful. Dedicated to making a difference for the betterment of all involved. That’s Duggan Investments.About Bob
Duggan Investments focuses on groundbreaking bioscience companies. With cancer treatment, anti-microbial treatment, anti-aging, and stem cell research, our involvement with these cutting-edge technologies is to improve life for all.
The conditions of life can and need to improve for the betterment of all involved.